| The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK. | The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK.
Sato H, Ito T, Hayashi T, Kitano S, Erdjument-Bromage H, Bott MJ, Toyooka S, Zauderer M, Ladanyi M. | 05/6/2024 |
| Circ_0087851 suppresses colorectal cancer malignant progression through triggering miR-593-3p/BAP1-mediated ferroptosis. | Circ_0087851 suppresses colorectal cancer malignant progression through triggering miR-593-3p/BAP1-mediated ferroptosis.
Huang M, Gao T, Chen X, Yi J, Zhou X., Free PMC Article | 05/6/2024 |
| Functional assay for assessment of pathogenicity of BAP1 variants. | Functional assay for assessment of pathogenicity of BAP1 variants.
Repo PE, Backlund MP, Kivelä TT, Turunen JA., Free PMC Article | 02/22/2024 |
| Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma. | Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
Takeda K, Bastacky S, Dhir R, Mohebnasab M, Quiroga-Garza GM. | 02/9/2024 |
| Balanced Epigenetic Regulation of MHC Class I Expression in Tumor Cells by the Histone Ubiquitin Modifiers BAP1 and PCGF1. | Balanced Epigenetic Regulation of MHC Class I Expression in Tumor Cells by the Histone Ubiquitin Modifiers BAP1 and PCGF1.
Wijdeven RH, Luk SJ, Schoufour TAW, van der Zanden SY, Cabezuelo M, Heemskerk MHM, Neefjes J. | 01/26/2024 |
| Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma. | Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma.
Chen Y, Du X, Gao Y, Wu H, Zhao H, Su Y., Free PMC Article | 12/20/2023 |
| Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology. | Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G, Özekinci S. | 11/7/2023 |
| BAP1 promotes osteoclast function by metabolic reprogramming. | BAP1 promotes osteoclast function by metabolic reprogramming.
Rohatgi N, Zou W, Li Y, Cho K, Collins PL, Tycksen E, Pandey G, DeSelm CJ, Patti GJ, Dey A, Teitelbaum SL., Free PMC Article | 09/28/2023 |
| BAP1 mutations inhibit the NF-kappaB signaling pathway to induce an immunosuppressive microenvironment in uveal melanoma. | BAP1 mutations inhibit the NF-κB signaling pathway to induce an immunosuppressive microenvironment in uveal melanoma.
Zhang C, Wu S., Free PMC Article | 09/20/2023 |
| BAP1 as a guardian of genome stability: implications in human cancer. | BAP1 as a guardian of genome stability: implications in human cancer.
Kwon J, Lee D, Lee SA., Free PMC Article | 08/25/2023 |
| Investigating the Role of FoxP3 in Renal Cell Carcinoma Metastasis with BAP1 or SEDT2 Mutation. | Investigating the Role of FoxP3 in Renal Cell Carcinoma Metastasis with BAP1 or SEDT2 Mutation.
Xu S, Hu X, Chong Y, Zhu G., Free PMC Article | 08/14/2023 |
| Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1. | Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.
Thomas JF, Valencia-Sánchez MI, Tamburri S, Gloor SL, Rustichelli S, Godínez-López V, De Ioannes P, Lee R, Abini-Agbomson S, Gretarsson K, Burg JM, Hickman AR, Sun L, Gopinath S, Taylor HF, Sun ZW, Ezell RJ, Vaidya A, Meiners MJ, Cheek MA, Rice WJ, Svetlov V, Nudler E, Lu C, Keogh MC, Pasini D, Armache KJ., Free PMC Article | 08/11/2023 |
| Two unique BAP1 pathogenic variants identified in the same family by panel cascade testing. | Two unique BAP1 pathogenic variants identified in the same family by panel cascade testing.
Byrne L, Ingalls C, Ansari A, Porteus C, Donenberg TR, Sussman DA, Cebulla CM, Abdel-Rahman MH., | 06/22/2023 |
| BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study. | BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.
Friedhoff J, Schneider F, Jurcic C, Endris V, Kirchner M, Sun A, Bolnavu I, Pohl L, Teroerde M, Kippenberger M, Schwab C, Kaczorowski A, Zschäbitz S, Jäger D, Hohenfellner M, Stenzinger A, Duensing A, Duensing S., Free PMC Article | 05/30/2023 |
| Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss. | Organoid models of fibrolamellar carcinoma mutations reveal hepatocyte transdifferentiation through cooperative BAP1 and PRKAR2A loss.
Rüland L, Andreatta F, Massalini S, Chuva de Sousa Lopes S, Clevers H, Hendriks D, Artegiani B., Free PMC Article | 05/9/2023 |
| BAP1-deficient meningioma presenting with trabecular architecture and cytokeratin expression: a report of two cases and review of the literature. | BAP1-deficient meningioma presenting with trabecular architecture and cytokeratin expression: a report of two cases and review of the literature.
Landry AP, Wang JZ, Nassiri F, Patil V, Gao A, Zadeh G. | 04/24/2023 |
| Basis of the H2AK119 specificity of the Polycomb repressive deubiquitinase. | Basis of the H2AK119 specificity of the Polycomb repressive deubiquitinase.
Ge W, Yu C, Li J, Yu Z, Li X, Zhang Y, Liu CP, Li Y, Tian C, Zhang X, Li G, Zhu B, Xu RM. | 04/15/2023 |
| Histopathologic and molecular characterization of BAP-1-inactivated melanoma. | Histopathologic and molecular characterization of BAP-1-inactivated melanoma.
Miller EM, Linos K, Bacchi CE, Gru AA, Raghavan SS. | 03/24/2023 |
| Analysis of uveal melanomas and paired constitutional DNA for exclusion of a BAP1-tumor predisposition syndrome. | Analysis of uveal melanomas and paired constitutional DNA for exclusion of a BAP1-tumor predisposition syndrome.
Abbassi YA, Le Guin C, Bornfeld N, Bechrakis NE, Zeschnigk M, Lohmann DR., Free PMC Article | 03/23/2023 |
| The expanding role of BAP1 in clear cell renal cell carcinoma. | The expanding role of BAP1 in clear cell renal cell carcinoma.
Kapur P, Rajaram S, Brugarolas J., Free PMC Article | 03/22/2023 |
| PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma. | PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.
Walton J, Lawson K, Prinos P, Finelli A, Arrowsmith C, Ailles L. | 03/2/2023 |
| DNA methylation of GITR, OX40, 4-1BB, CD27 , and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma. | DNA methylation of GITR, OX40, 4-1BB, CD27 , and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma.
Hoffmann F, Fröhlich A, Sirokay J, de Vos L, Zarbl R, Dietrich J, Strieth S, Landsberg J, Dietrich D. | 02/27/2023 |
| BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms. | BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms.
Singh A, Busacca S, Gaba A, Sheaff M, Poile C, Nakas A, Dzialo J, Bzura A, Dawson AG, Fennell DA, Fry AM., Free PMC Article | 02/27/2023 |
| Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. | Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma.
Pandey GK, Landman N, Neikes HK, Hulsman D, Lieftink C, Beijersbergen R, Kolluri KK, Janes SM, Vermeulen M, Badhai J, van Lohuizen M., Free PMC Article | 02/26/2023 |
| BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma. | BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma.
Devins KM, Zukerberg L, Watkins JC, Hung YP, Oliva E. | 02/14/2023 |